BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecke HR. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging 2012;39:1876-85. [DOI: 10.1007/s00259-012-2231-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Nock BA, Kanellopoulos P, Moon ES, Rouchota M, Loudos G, Ballal S, Yadav MP, Bal C, Mishra P, Sheokand P, Roesch F, Maina T. [111In]In/[177Lu]Lu-AAZTA5-LM4 SST2R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results. Pharmaceutics 2023;15:776. [DOI: 10.3390/pharmaceutics15030776] [Reference Citation Analysis]
2 Makris G, Li Y, Gallazzi F, Kuchuk M, Wang J, Lewis MR, Jurisson SS, Hennkens HM. Evaluation of Re/99mTc-labeled somatostatin receptor-targeting peptide complexes synthesized via direct metal cyclization. Radiochimica Acta 2023;0. [DOI: 10.1515/ract-2022-0097] [Reference Citation Analysis]
3 Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne) 2022;9:1034315. [PMID: 36569154 DOI: 10.3389/fmed.2022.1034315] [Reference Citation Analysis]
4 Fani M, Mansi R, Nicolas GP, Wild D. Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. Cancers (Basel) 2022;14:1172. [PMID: 35267479 DOI: 10.3390/cancers14051172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Maleki F, Farahani AM, Rezazedeh F, Sadeghzadeh N. Structural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging. Bioorganic Chemistry 2020;99:103802. [DOI: 10.1016/j.bioorg.2020.103802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Haug A. Nuclear Medicine Imaging Techniques of the Neuroendocrine System. Clinical Nuclear Medicine 2020. [DOI: 10.1007/978-3-030-39457-8_13] [Reference Citation Analysis]
7 Behnammanesh H, Jokar S, Erfani M, Geramifar P, Sabzevari O, Amini M, Mazidi SM, Hajiramezanali M, Beiki D. Design, preparation and biological evaluation of a 177Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors. Bioorganic Chemistry 2020;94:103381. [DOI: 10.1016/j.bioorg.2019.103381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Makris G, Radford LL, Kuchuk M, Gallazzi F, Jurisson SS, Smith CJ, Hennkens HM. NOTA and NODAGA [99mTc]Tc- and [186Re]Re-Tricarbonyl Complexes: Radiochemistry and First Example of a [99mTc]Tc-NODAGA Somatostatin Receptor-Targeting Bioconjugate. Bioconjug Chem 2018;29:4040-9. [PMID: 30412382 DOI: 10.1021/acs.bioconjchem.8b00670] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
9 Abiraj K, Ursillo S, Tamma ML, Rylova SN, Waser B, Constable EC, Fani M, Nicolas GP, Reubi JC, Maecke HR. The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist. EJNMMI Res 2018;8:75. [PMID: 30069789 DOI: 10.1186/s13550-018-0428-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
10 Okarvi SM, Maecke HR. Radiolabelled peptides in medical imaging. Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Elsevier; 2018. pp. 431-83. [DOI: 10.1016/b978-0-08-100736-5.00019-3] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
11 Fani M, Nicolas GP, Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J Nucl Med. 2017;58:61S-66S. [PMID: 28864614 DOI: 10.2967/jnumed.116.186783] [Cited by in Crossref: 131] [Cited by in F6Publishing: 137] [Article Influence: 21.8] [Reference Citation Analysis]
12 Ilias I, Meristoudis G. Functional Imaging of Paragangliomas with an Emphasis on Von Hippel-Lindau-Associated Disease: A Mini Review. J Kidney Cancer VHL 2017;4:30-6. [PMID: 28890865 DOI: 10.15586/jkcvhl.2017.92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ. [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics 2017;7:2350-62. [PMID: 28744319 DOI: 10.7150/thno.19119] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
14 Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging 2017;44:1588-601. [DOI: 10.1007/s00259-017-3728-y] [Cited by in Crossref: 197] [Cited by in F6Publishing: 150] [Article Influence: 32.8] [Reference Citation Analysis]
15 Fani M, Peitl PK, Velikyan I. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals (Basel) 2017;10:E30. [PMID: 28295000 DOI: 10.3390/ph10010030] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
16 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26067-9_17-3] [Reference Citation Analysis]
17 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26067-9_17-2] [Reference Citation Analysis]
18 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26236-9_17] [Reference Citation Analysis]
19 Krebs S, Dunphy M. Role of nuclear medicine in diagnosis and management of hepatopancreatobiliary disease. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00017-0] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
20 Radford L, Gallazzi F, Watkinson L, Carmack T, Berendzen A, Lewis MR, Jurisson SS, Papagiannopoulou D, Hennkens HM. Synthesis and evaluation of a 99mTc tricarbonyl-labeled somatostatin receptor-targeting antagonist peptide for imaging of neuroendocrine tumors. Nucl Med Biol 2017;47:4-9. [PMID: 28043006 DOI: 10.1016/j.nucmedbio.2016.12.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
21 Hicks RJ. Citius, Altius, Fortius: An Olympian Dream for Theranostics. J Nucl Med 2017;58:194-5. [DOI: 10.2967/jnumed.116.182188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
22 Perreault A, Richter S, Bergman C, Wuest M, Wuest F. Targeting Phosphatidylserine with a 64 Cu-Labeled Peptide for Molecular Imaging of Apoptosis. Mol Pharmaceutics 2016;13:3564-77. [DOI: 10.1021/acs.molpharmaceut.6b00666] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
23 Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. Tumour Biol 2016;37:12991-3003. [PMID: 27460087 DOI: 10.1007/s13277-016-5258-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
24 Valverde IE, Vomstein S, Mindt TL. Toward the Optimization of Bombesin-Based Radiotracers for Tumor Targeting. J Med Chem 2016;59:3867-77. [PMID: 27054526 DOI: 10.1021/acs.jmedchem.6b00025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
25 Okarvi SM, Maecke HR. Radiometallo-Labeled Peptides in Tumor Diagnosis and Targeted Radionuclide Therapy. Insights from Imaging in Bioinorganic Chemistry. Elsevier; 2016. pp. 341-96. [DOI: 10.1016/bs.adioch.2015.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
26 Tabacchi E, Nanni C, Bossert I, Maffione AM, Fanti S. Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. Nuclear Oncology 2016. [DOI: 10.1007/978-3-319-26067-9_17-1] [Reference Citation Analysis]
27 Sabet A, Biersack H, Ezziddin S. Advances in Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine 2016;46:40-6. [DOI: 10.1053/j.semnuclmed.2015.09.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
28 Werner RA, Bluemel C, Lassmann M, Kudlich T, Higuchi T, Lopci E, Allen-Auerbach M, Colletti PM, Rubello D, Zatelli MC, Herrmann K. SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach. Clin Nucl Med 2015;40:e271-7. [PMID: 25642915 DOI: 10.1097/RLU.0000000000000729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
29 Accardo A, Morelli G. Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues: Peptide-Targeted Liposomes for Selective Drug Delivery. Biopolymers 2015;104:462-79. [DOI: 10.1002/bip.22678] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
30 Valverde IE, Vomstein S, Fischer CA, Mascarin A, Mindt TL. Probing the Backbone Function of Tumor Targeting Peptides by an Amide-to-Triazole Substitution Strategy. J Med Chem 2015;58:7475-84. [DOI: 10.1021/acs.jmedchem.5b00994] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
31 Fani M, Maecke HR. Radiolabeled Somatostatin Receptor Antagonists. Somatostatin Analogues 2015. [DOI: 10.1002/9781119031659.ch27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Kaminski G. New methods of nuclear medicine in thyroid. Thyroid Research 2015;8:A14. [DOI: 10.1186/1756-6614-8-s1-a14] [Reference Citation Analysis]
33 de Herder WW. GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs). Eur J Endocrinol 2014;170:R173-83. [PMID: 24723670 DOI: 10.1530/EJE-14-0077] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
34 Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, Kwekkeboom DJ, de Jong M. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging 2014;2:55-66. [PMID: 24765618 DOI: 10.1007/s40336-014-0054-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
35 Adriaenssens L, Liu Q, Chaux-picquet F, Tasan S, Picquet M, Denat F, Le gendre P, Marques F, Fernandes C, Mendes F, Gano L, Campello MPC, Bodio E. Novel Heterobimetallic Radiotheranostic: Preparation, Activity, and Biodistribution. ChemMedChem 2014;9:1567-73. [DOI: 10.1002/cmdc.201300494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
36 Fahey F, Zukotynski K, Capala J, Knight N; Organizing Committee, Contributors, and Participants of NCI/SNMMI Joint Workshop on Targeted Radionuclide Therapy. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Med 2014;55:337-48. [PMID: 24396032 DOI: 10.2967/jnumed.113.135178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
37 Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nuclear Medicine and Biology 2013;40:1025-34. [DOI: 10.1016/j.nucmedbio.2013.07.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
38 Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. [PMID: 23476673 DOI: 10.1155/2013/926295] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 7.0] [Reference Citation Analysis]
39 Behnammanesh H, Erfani M, Hajiramezanali M, Jokar S, Geramifar P, Sabzevari O, Amini M, Mazidi SM, Beiki D. Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells. Asia Ocean J Nucl Med Biol 2020;8:109-15. [PMID: 32714998 DOI: 10.22038/AOJNMB.2020.44432.1299] [Cited by in F6Publishing: 2] [Reference Citation Analysis]